La cadena de opciones muestra datos clave de las opciones de acciones de 10x Genomics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para 10x Genomics..

10x Genomics (NASDAQ:TXG) Bolsa, Cadena de Opciones

10x Genomics

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Equities

News

ETFs

ACHR

ARKK

PLTR

QCOM

RBLX

Ark Invest vendió acciones de Palantir por 10,4M$. ¿Qué impulsó esta decisión y qué significa para los inversionistas?

Ark Invest ajusta su portafolio: venta masiva de Palantir y nuevas compras estratégicas

10x Genomics Inc

TEXAS GULF ENERGY INC by Texas Gulf Energy, Incorporated.

Texas Gulf Energy Inc

WIIM

ARBE

Arbe Robotics shares are trading lower after the company reported worse-than-expected Q4 financial results.

Jefferies analyst Joseph Gallo maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and lowers the price target from $450 to $425.

Price Target

Analyst Ratings

CRWD

Jefferies Maintains Buy on CrowdStrike Holdings, Lowers Price Target to $425

Blockchain analytics firm bitsCrunch has acquired Nidum AI, a decentralized AI computing platform, to establish a global network of high-performance AI compute nodes, the company announced on Wednesday. 
The acquisition integrates Nidum AI's distributed computational resources into bitsCrunch's operations, aiming to enhance AI-driven analytics for blockchain applications. 
Alongside the purchase, bitsCrunch launched a decentralized AI ecosystem, designating its (CRYPTO: BCUT) token as the sole currency for accessing services within this network.
The deal brings Nidum AI's infrastructure—connecting AI developers with computational power worldwide—under bitsCrunch's umbrella, a move rooted in the latter's focus on blockchain forensics and data insights. 
The ecosystem employs Tensor and Pipeline parallelism to split complex AI tasks across multiple nodes, targeting faster model training and inference for applications like fraud detection and risk assessment. 
bitsCrunch claims this structure cuts costs to roughly 1/100th of competitors like OpenAI and Grok, though independent verification of this figure remains pending. 
The $BCUT token, already traded on exchanges such as ByBit, KuCoin, and Uniswap (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/uni/usd">UNI</a>), will now facilitate payments for these services, tying its utility directly to the ecosystem's functionality.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44145022/nba-legend-shaq-never-held-bitcoin-or-xrp-but-theres-one-other-trump-crypto-reserve-coin-he-bought-in-2021">NBA Legend Shaq Never Held Bitcoin Or XRP, But There&#8217;s One Other Trump Crypto Reserve Coin He Bought In 2021 &#8211; Benzinga</a>
Vijay Pravin, bitsCrunch's Founder and CEO, framed the acquisition as a strategic expansion with global implications. 
"This strategic acquisition demonstrates the scale of our ambition to be a leading force in the decentralization of AI," he said, noting Nidum AI's origins as an Indian counterpoint to centralized AI giants like OpenAI. 
"Our native $BCUT token will serve as the exclusive currency of a thriving, decentralized AI marketplace," he added, emphasizing its role in linking users and developers. 
The ecosystem targets financial institutions, regulators, and investors, offering tools for real-time compliance and threat detection in digital transactions.
The acquisition follows bitsCrunch's work in multi-chain analytics, where it serves retail and institutional clients with AI-powered forensics. 
Nidum AI's technology adds a layer of distributed computing power, potentially broadening bitsCrunch's reach into industries reliant on scalable AI. 
However, the integration's success hinges on execution—connecting a global developer base with compute resources poses logistical and technical challenges. 
Competing platforms like io.net (CRYPTO: IO) and Gaia (CRYPTO: GAIA) also vie for dominance in decentralized AI computing, raising questions about bitsCrunch's ability to differentiate itself beyond cost claims.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44141114/trumps-xrp-cardano-inclusion-in-crypto-reserve-proposal-could-be-result-of-businessman-instincts-mexcs-tracy-jin-says">Trump&#8217;s XRP, Cardano Inclusion In Crypto Reserve Proposal Could Be Result Of &#8216;Businessman&#8217; Instincts, MEXC&#8217;s Tracy Jin Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$UNI

BitsCrunch Acquires Nidum AI To Build Decentralized AI Compute Network

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on BioNTech SE&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) Investigational New Drug application (IND) and the related Phase 1/2a trial evaluating the safety, tolerability, immunogenicity, and efficacy of an investigational RNA-based vaccine (BNT165e) for prevention of P. falciparum <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">malaria in healthy malaria-naive adults</a>.
The multi-antigen malaria vaccine (designated BNT165e) is a combination of three distinct RNAs, BNT165c and BNT165d (composed of BNT165d1 and BNT165d2).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42925721/biontech-positioned-for-long-term-growth-amid-oncology-transition" rel="noreferrer noopener">BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst</a>
The <a target="_blank" href="https://clinicaltrials.biontech.com/trials/BNT165-02" rel="noreferrer noopener">trial</a> was expected to enroll around 177 participants and conclude in September 2025. BioNTech has proactively paused the study, the SEC <a target="_blank" href="https://investors.biontech.de/node/16966/html" rel="noreferrer noopener">filing</a> noted, and is taking actions to address the FDA&#8217;s requests and will work with the FDA to assess the next steps.
In October, the FDA imposed a partial clinical hold on BioNTech&#8217;s partner,&nbsp;OncoC4 Inc.&#8217;s Phase 3 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41434586/fda-presses-clinical-hold-button-for-biontechs-partner-late-stage-trial-of-investigational-lung-c" rel="noreferrer noopener">PRESERVE-003 trial</a>. Varying outcomes between patients with squamous and non-squamous non-small cell lung cancer triggered the partial hold.
Also in August, the FDA lifted the partial clinical hold on MediLink Therapeutics&#8217; Phase 1 trial for BNT326/YL202, a HER3-targeting <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40440731/fda-allows-resumption-of-biontechmedilink-therapeutics-partnered-phase-1-study-for-cancer-drug-wi" rel="noreferrer noopener">antibody-drug conjugate</a>.
The decision, announced on August 15, follows the submission of a complete response that includes data analysis, updated documentation, and additional risk mitigation measures.
Price Action: BNTX stock is up 3.11% at $113.06&nbsp;at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44145025/dine-brands-q4-earnings-beat-estimates-sales-dip-on-lower-franchise-revenues" target="_blank" rel="noreferrer noopener">Dine Brands Q4 Earnings: Sales Dip, EPS Miss, Negative Comps For Applebee&#8217;s, IHOP And More</a></li>
</ul>

Biotech

Health Care

Movers

General

BNTX

FDA Places Clinical Hold On BioNTech's Early-Phase Trial For RNA-Based Malaria Vaccine

Palantir Technologies shares are trading higher after William Blair upgraded the stock from Underperform to Market Perform.

Several analysts boosted the price forecast for AutoZone, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) following second-quarter&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/azo/analyst-ratings" rel="noreferrer noopener">results reported on Tuesday</a>.
The company reported second-quarter GAAP earnings per share of $28.29,&nbsp;missing the street view of $29.39 and sales of $3.952 billion (+2.4% year over year) missed the analyst <a target="_blank" href="https://www.benzinga.com/25/03/44107516/autozone-q2-earnings-miss-estimates-revenues-grow-24" rel="noreferrer noopener">consensus estimate of $3.981 billion</a>.
Raymond James analyst Bobby Griffin maintained a Strong Buy rating and raised the price target from&nbsp;$3,850&nbsp;to&nbsp;$4,000.
The analyst writes that they remain optimistic about the company&#8217;s strong commercial performance, resilient gross margins, and long-term growth prospects despite lowering the FY25 EPS estimate to $153.10 (from $154.85).
The analyst says that the International growth, with ~100 new stores, remains a bright spot, despite near-term foreign exchange headwinds.
The Mega-Hub expansion remains key, with plans for 300 locations to boost both domestic retail (DIY) and DIFM availability, per the analyst.&nbsp;&nbsp;
Griffin writes that DIFM sales are rising, supported by better inventory placement and faster delivery.
While DIY traffic is under pressure, AZO is poised for a rebound as macro conditions improve, with potential upside from inflation and tariff effects, adds the analyst.
Guggenheim analyst Steven Forbes retained a Buy rating and raised the price forecast from&nbsp;$3,750&nbsp;to&nbsp;$3,850.
The analyst writes that the results support his thesis of continued sequential improvement, highlighted by stronger DIY and DIFM comps.
While higher-than-expected investments in field labor led to a slight EBIT(DA) shortfall, the analyst anticipates these investments will mature in the next 12 months, setting up for stronger comp growth in the second half of 2025.
Other price forecast revisions include:
<ul>
<li>DA Davidson analyst Michael Baker maintained a Neutral rating and boosted the price forecast from $3,350 to $3,500.</li>
<li>Evercore ISI Group analyst Greg Melich kept an Outperform rating and upped the price forecast from $3,525 to $3,700.</li>
<li>JP Morgan analyst Christopher Horvers reaffirmed an Overweight and increased the price forecast from $3,775 to $3,830.</li>
<li>BMO Capital analyst Tristan Thomas-Martin retained an Outperform and raised the price forecast from $3,700 to $3,850.</li>
<li>Morgan Stanley analyst Simeon Gutman maintained an Overweight and upped the price forecast from $3,490 to $3,750.</li>
<li>Mizuho analyst David Bellinger kept an Outperform and boosted the price forecast from $3,600 to $3,740.</li>
</ul>
Investors can gain exposure to the stock via Exchange Listed Funds Trust Bancreek U.S. Large Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCUS#NYSE">BCUS</a>) and VanEck Retail ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTH#NASDAQ">RTH</a>).
Price Action: AZO shares are up 2.36% at $3,555.56 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43388778/jim-cramer-autozone-is-a-great-stock-recommends-buying-this-energy-stock" target="_blank" rel="noreferrer noopener">Jim Cramer: AutoZone Is A &#8216;Great&#8217; Stock, Recommends Buying This Energy Stock</a></li>
</ul>
Photo by Shuttershock.

Analyst Color

Large Cap

Reiteration

Trading Ideas

BCUS

Merrill Lynch Retail HOLDRS Trust due 12/31/41

AutoZone's Growth Story Intact, Analysts Highlight Commercial Strength and Expansion Plans

Fulcrum Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) received written notice from MyoKardia, Inc. for the termination of the collaboration and license agreement <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">dated July 20, 2020</a>.
Under the agreement, Fulcrum had granted MyoKardia an exclusive worldwide license to discover, develop, and commercialize novel targeted therapies for genetic cardiomyopathies.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40837254/fulcrum-therapeutics-suspends-rare-muscular-disease-candidate-after-disappointing-data-from-pivot" rel="noreferrer noopener">Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial</a>
Under the agreement, under a mutually agreed research plan, Fulcrum agreed to perform assay screening and related research activities to identify and validate up to a specified number of potential cardiomyopathy gene targets for further research, development, manufacture, and commercialization by MyoKardia.
MyoKardia paid Fulcrum $10.0 million upfront and $2.5 million in prepaid research funding. It also agreed to reimburse Fulcrum for the costs of research activities not covered by the prepaid research funding up to a maximum of the total research funding.
Upon the achievement of specified milestones, Fulcrum would have been entitled to preclinical milestone payments, development milestone payments and sales-based milestone payments of up to $298.5 million in the aggregate per target for certain identified targets, and of up to $150.0 million in the aggregate per target for certain other identified targets.
Fulcrum achieved a $2.5 million specified preclinical milestone. MyoKardia also agreed to pay Fulcrum tiered royalties ranging from a mid-single-digit percentage to a low double-digit percentage.
In 2020, Bristol Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) acquired <a target="_blank" href="https://www.benzinga.com/general/biotech/21/05/21147817/bristol-myers-unveils-more-mavacamten-data-to-backup-case-for-heart-drug" rel="noreferrer noopener">MyoKardia for $13.1 billion</a>.
As per the SEC <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1680581/000095017025032355/fulc-20250226.htm" rel="noreferrer noopener">filing</a>, the termination will become effective on June 26, 2025.
Price Action: FULC stock is up 1.38% at $3.32 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/03/44144092/why-is-hims-hers-health-stock-trading-lower-on-wednesday" target="_blank" rel="noreferrer noopener">Why Is Hims &amp; Hers Health Stock Trading Lower On Wednesday?</a></li>
</ul>

Contracts

FULC

Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal

Vladimir Tenev, <a href="https://www.benzinga.com/money/robinhood-review">co-founder and CEO</a> of Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), on Wednesday affirmed that cryptocurrency infrastructure, or "crypto rails," will serve as the foundation for stocks and other traditional assets.
What Happened: In a fireside chat, Tenev emphasized the potential of blockchain technology to revolutionize trading, citing its 24/7 availability and cost efficiencies as key advantages for integrating stocks onto decentralized platforms.
This vision comes as Robinhood, known for its commission-free trading, expands its offerings amid growing regulatory and technological changes in the U.S. financial sector.
Tenev's <a href="https://x.com/TheOneandOmsy/status/1897119276081012788">comments</a> highlight crypto's role in bridging speculative digital assets like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and meme coins with real-world financial products.
"There's no reason why you should be able to invest in a meme coin freely as much as you want, but SpaceX and OpenAI are too risky," he said, highlighting the need to apply crypto's infrastructure to more stable, productive assets. 
He noted that blockchain's inherent 24/7 operation, enabled by decentralized finance protocols, could simplify 24/7 stock trading—a feature Robinhood already offers for over 1,000 stocks through its platform.
"Crypto by its nature is 24/7. It's running on blockchain technology that doesn't close on weekends," Tenev explained, pointing to the engineering challenges of stitching together market centers for seamless, noncustodial trading experiences.
The CEO acknowledged regulatory hurdles in the U.S., where crypto has faced restrictions that limit its connection to traditional assets.
"It has been a little bit of an unfair criticism of the crypto industry because the problem is we have not been allowed in the U.S. up until now to connect crypto to real-world productive assets because that's where the security laws have come in," he stated.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44145022/nba-legend-shaq-never-held-bitcoin-or-xrp-but-theres-one-other-trump-crypto-reserve-coin-he-bought-in-2021">NBA Legend Shaq Never Held Bitcoin Or XRP, But There&#8217;s One Other Trump Crypto Reserve Coin He Bought In 2021</a>
Why It Matters: Despite these barriers, Tenev sees a massive opportunity for companies like Robinhood, which he believes is well-positioned to lead.
He suggested that two or three MIT engineers, leveraging DeFi tools, could easily build a platform offering stocks and other assets on noncustodial wallets, creating both a "scary thought" for competitors and a "huge opportunity" for Robinhood.
Tenev's remarks align with the current administration's embrace of crypto and AI as strategic priorities, as he noted during an Investor Day discussion. 
He plans to attend the White House Crypto Summit in Washington, D.C., on Friday, Mar. 7 to ensure the U.S. leads in this domain. 
His vision extends beyond crypto's speculative phase, advocating for its underlying infrastructure to underpin securities, commodities, and other real-world assets. 
"I think we'll have to fix that. And I think there's huge advantages in crypto technology being the underlying infrastructure behind all types of assets, securities, commodities, other real-world assets," he said, positioning Robinhood as a potential leader in this transformation.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44141114/trumps-xrp-cardano-inclusion-in-crypto-reserve-proposal-could-be-result-of-businessman-instincts-mexcs-tracy-jin-says">Trump&#8217;s XRP, Cardano Inclusion In Crypto Reserve Proposal Could Be Result Of &#8216;Businessman&#8217; Instincts, MEXC&#8217;s Tracy Jin Says</a></li>
</ul>
Image: Shutterstock

$BTC

HOOD

Robinhood CEO Vlad Tenev Expects 'Crypto Rails' To Become The Foundation Of Stock Trading

Macro Economic Events

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher as investors assess trade tensions and Trump's address to Congress. It was reported that Trump is weighing a potential auto tariff delay.

DA Davidson analyst Michael Baker maintains BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) with a Buy and lowers the price target from $5 to $3.

BRCC

DA Davidson Maintains Buy on BRC, Lowers Price Target to $3

JP Morgan analyst Mark Murphy upgraded Intuit Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) from Neutral to Overweight and raised the <a target="_blank" href="https://www.benzinga.com/quote/INTU/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$640&nbsp;to&nbsp;$660</a>.
Murphy maintained his view of Intuit as a dependable, innovative, and scaled cloud platform that serves consumers, self-employed, small businesses, and mid-market customers while serving as a good steward of capital. The analyst noted stable-to-positive trending across Intuit's core businesses.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43980437/intuit-sees-ai-driven-growth-with-turbotax-credit-karma-analyst-raises-price-forecast" rel="noreferrer noopener">Intuit Sees AI-Driven Growth With TurboTax, Credit Karma: Analyst Raises Price Forecast</a>
However, risks continue to arise from macro volatility, policy uncertainties, and other idiosyncratic and external variables.
Intuit stock has underperformed to such an extent that it trades below where it was ~3.5 years ago when the term "transitory inflation" was retired in November 2021.
It underperformed versus the S&amp;P 500 by ~3,700 bps (-14% versus +23%) and underperformed versus mega-cap software by an even more considerable margin (-14% versus +30%). This occurred despite Intuit being a widely-held consensus long, with 83% of ratings being buy-equivalent in November 2021.
Some speedbumps were encountered, including a Credit Karma growth reset, a perceived loss of TurboTax market share in recent Tax seasons, and a reduction in long-term growth target models for the Credit Karma and Tax businesses.
However, the company has innovated and executed quite well along many other dimensions, and most of the stock's underperformance has stemmed from a valuation reset, he noted.
The updated price target reflects a shift in peer group multiples and other considerations. The multiple is above the comp group of Scaled Software Vendors with ~10%+ calendar 2026E growth and/or ~20%+ uFCF margin (ORCL, ADBE, CRM, SNPS, ADSK, VEEV, CSPG, and BOX), which trade at ~2.3x on average.
Murphy noted that Intuit warranted a premium to account for the company's relatively less competitive core markets, superior stickiness, and higher perceived value-versus price-paid of the core QuickBooks franchise, leading to a higher pricing envelope and lower volatility of the annual growth profile.
Murphy projected third-quarter revenue of $7.51 billion and adjusted EPS of $10.92.
INTU Price Action: INTU stock is up 1.81% at $608.88 at the time of publication on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44087877/intel-stock-surges-as-nvidia-broadcom-test-18a-chips-amd-shows-interest" target="_blank" rel="noreferrer noopener">Intel Gains Traction With 18A Process As Nvidia, Broadcom Consider Manufacturing Contracts</a></li>
</ul>
Intuit via Shutterstock

Upgrades

INTU

Intuit Under-performance Has Stemmed From Valuation Reset, Analyst Upgrades Stock

Deep-pocketed investors have adopted a bearish approach towards Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in COIN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 14 extraordinary options activities for Coinbase Global. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 14% leaning bullish and 28% bearish. Among these notable options, 11 are puts, totaling $504,274, and 3 are calls, amounting to $175,361.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $187.5 to $660.0 for Coinbase Global over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Coinbase Global's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Coinbase Global's whale trades within a strike price range from $187.5 to $660.0 in the last 30 days. 
<h3>Coinbase Global Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741198573_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COIN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$446.75</td>
<td>$443.35</td>
<td>$444.89</td>
<td>$660.00</td>
<td>$88.9K</td>
<td>112</td>
<td align="right">8</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$6.7</td>
<td>$6.5</td>
<td>$6.55</td>
<td>$300.00</td>
<td>$75.3K</td>
<td>1.3K</td>
<td align="right">53</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.6</td>
<td>$5.8</td>
<td>$6.13</td>
<td>$237.50</td>
<td>$56.3K</td>
<td>217</td>
<td align="right">101</td>
</tr>
<tr>
<td>COIN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$9.5</td>
<td>$8.95</td>
<td>$9.15</td>
<td>$200.00</td>
<td>$45.9K</td>
<td>16.2K</td>
<td align="right">554</td>
</tr>
<tr>
<td>COIN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$448.85</td>
<td>$445.5</td>
<td>$447.5</td>
<td>$660.00</td>
<td>$44.7K</td>
<td>112</td>
<td align="right">13</td>
</tr>
</tbody>
</table>

<h3>About Coinbase Global</h3>
Founded in 2012, Coinbase is the leading cryptocurrency exchange platform in the United States. The company intends to be the safe and regulation-compliant point of entry for retail investors and institutions into the cryptocurrency economy. Users can establish an account directly with the firm, instead of using an intermediary, and many choose to allow Coinbase to act as a custodian for their cryptocurrency, giving the company breadth beyond that of a traditional financial exchange. While the company still generates the majority of its revenue from transaction fees charged to its retail customers, Coinbase uses internal investment and acquisitions to expand into adjacent businesses, such as prime brokerage and data analytics.
In light of the recent options history for Coinbase Global, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Coinbase Global</h3>
<ul>
<li>With a volume of 5,414,210, the price of COIN is up 1.75% at $216.26. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 57 days.</li>
</ul>
<h3>Professional Analyst Ratings for Coinbase Global</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $331.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Keefe, Bruyette &amp; Woods keeps a Market Perform rating on Coinbase Global with a target price of $305. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Coinbase Global with a target price of $310. 
&#x2A; An analyst from Canaccord Genuity persists with their Buy rating on Coinbase Global, maintaining a target price of $400. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Neutral rating on Coinbase Global with a target price of $311. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $330. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Coinbase Global with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

COIN

Coinbase Global's Options Frenzy: What You Need to Know

DA Davidson analyst Peter Heckmann maintains CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) with a Buy and raises the price target from $36 to $38.

PMTS

DA Davidson Maintains Buy on CPI Card, Raises Price Target to $38

LTRY

Lottery.com Announces Ad-Supported Model

CIBC analyst Paul Holden maintains Toronto-Dominion Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TD#TSX">TD</a>) with a Outperformer and lowers the price target from C$96 to C$95.

TSX:TD

CIBC Maintains Outperformer on Toronto-Dominion Bank, Lowers Price Target to C$95

Politics

President Trump Says He Spoke To Trudeau About Tariffs; The Call Ended In A "Somewhat" Friendly Manner; Fentanyl Efforts Not Good Enough

B of A Securities analyst Ruplu Bhattacharya maintains Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy and lowers the price target from $30 to $28.

INGM

B of A Securities Maintains Buy on Ingram Micro Holding, Lowers Price Target to $28

CIBC analyst Paul Holden maintains Royal Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RY#TSX">RY</a>) with a Neutral and lowers the price target from C$175 to C$167.

TSX:RY

CIBC Maintains Neutral on Royal Bank of Canada, Lowers Price Target to C$167

B of A Securities analyst Alec Stranahan maintains Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Neutral and lowers the price target from $14 to $12.

YMAB

B of A Securities Maintains Neutral on Y-mAbs Therapeutics, Lowers Price Target to $12

B of A Securities analyst Tim Anderson maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Neutral and raises the price target from $159 to $171.

B of A Securities Maintains Neutral on Johnson & Johnson, Raises Price Target to $171

Press Releases

10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference

U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products

10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Earnings

10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results

10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025

Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology

10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products

BRKR

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

10x Genomics

10x Genomics (TXG) Opciones

10x Genomics (NASDAQ:TXG) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL